US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Militia Long/Short Equity ETF

38.51

-0.0144-0.04%

Volume:29.82K

Turnover:1.15M

Market Cap:351.21M

PE:- -

High:38.62

Open:38.50

Low:38.35

Close:38.52

52wk High:39.80

52wk Low:30.66

Shares:9.12M

Float Shares:9.12M

Volume Ratio:1.02

T/O Rate:0.33%

Dividend:- -

Dividend Rate:- -

ROE:--

ROA:--

PB:--

PE(LYR):- -

Loading ...

Overview Company News Filings

Prestige Biopharma Announces Positive Topline Results from Comparative SAMSON-II Study for HD204, a Potential Biosimilar to Avastin (bevacizumab)

Amplia Therapeutics Reports Four Additional Complete Responses and Improved Overall Survival Data in Accent Pancreatic Cancer Trial

Press Release: Pyxis Oncology Provides Business Update and Reports Fourth Quarter and Full Year 2025 Financial Results

Cellectis Reports Full Year 2025 Financial Results and Provides a Business Update

NovaBridge Announces Productive FDA Type B Meeting on Potential Accelerated Approval Pathway for Givastomig in Gastric Cancer

CytomX’s Varsetatug Masetecan (EpCAM PROBODY® ADC) Continues to Demonstrate Positive Data Supporting Potential as a New Treatment Option in Late-Line Colorectal Cancer

SELLAS Life Sciences Announces Enrollment of First Patient in Newly Diagnosed First-Line AML Trial of SLS009

New Variable in Pan-KRAS Space: Valuation Gap Behind JAB-23E73's 38.5% ORR in Pancreatic Cancer

Press Release: Alpha Tau Announces Full Year 2025 Financial Results and Provides Corporate Update

Press Release: PMV Pharmaceuticals Reports Full Year 2025 Financial Results and Corporate Highlights

Press Release: BBOT Reports Fourth Quarter and Full Year 2025 Financial Results and Update on Corporate Progress

Press Release: Immatics Announces Full Year 2025 Financial Results and Business Update

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://sg.tigeractivity.com/stock/ORR/news?page=7"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"ORR","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"ORR\",,,,,undefined,":{"symbol":"ORR","market":"US","secType":"STK","nameCN":"Militia Long/Short Equity ETF","latestPrice":38.51,"timestamp":1788372467180,"preClose":38.5244,"halted":0,"volume":29821,"delay":0,"changeRate":-0.0003737890791291225,"floatShares":9120000,"shares":9120000,"eps":0,"marketStatus":"Trading","change":-0.0144,"latestTime":"09-02 14:14:39 EDT","open":38.5,"high":38.62,"low":38.345,"amount":1148079.87184,"amplitude":0.007138,"askPrice":38.54,"askSize":1000,"bidPrice":38.51,"bidSize":700,"shortable":3,"etf":1,"ttmEps":0,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1788379200000},"marketStatusCode":2,"adr":0,"exchange":"NASDAQ","adjPreClose":38.5244,"sharesOutstanding":12900000,"nav":38.93,"aum":355041600,"bidAskSpread":0,"postHourTrading":{"tag":"盘后","latestPrice":38.53,"preClose":38.5244,"latestTime":"19:59 EDT","volume":54,"amount":2079.9308,"timestamp":1788307179128,"change":0.0056,"changeRate":0.000145,"amplitude":0},"volumeRatio":1.019448,"impliedVol":0.1409,"impliedVolPercentile":0.4848},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"ORR\",,,,,undefined,":{"symbol":"ORR","floatShares":9120000,"roa":"--","roe":"--","lyrEps":0,"volumeRatio":1.019448,"shares":9120000,"dividePrice":0,"high":38.62,"amplitude":0.007138,"preClose":38.5244,"low":38.345,"week52Low":30.655,"pbRate":"--","week52High":39.8,"institutionHeld":0,"latestPrice":38.51,"committee":-0.176471,"eps":0,"divideRate":0,"volume":29821,"delay":0,"ttmEps":0,"open":38.5,"prevYearClose":34.16,"prevWeekClose":38.9187,"prevMonthClose":38.77,"prevQuarterClose":36.32,"fiveDayClose":38.9814,"twentyDayClose":39.29,"sixtyDayClose":35.59},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/ORR\",params:#limit:5,,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"ORR\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"ORR\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"ORR\",pageSize:20,pageCount:7,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2621809037","title":"Prestige Biopharma Announces Positive Topline Results from Comparative SAMSON-II Study for HD204, a Potential Biosimilar to Avastin (bevacizumab)","url":"https://stock-news.laohu8.com/highlight/detail?id=2621809037","media":"prnewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621809037?lang=en_us&edition=fundamental","pubTime":"2026-03-24 11:32","pubTimestamp":1774323120,"startTime":"0","endTime":"0","summary":"Primary endpoint of Overall Response Rate at Week 18 met, demonstrating clinical equivalence in patients with advanced non-squamous non-small cell lung cancer. SINGAPORE, March 24, 2026 /PRNewswire/ -- Prestige Biopharma today announced positivetopline results from its Phase 3 SAMSON-II study evaluating HD204, a proposed biosimilar to Avastin  in adult patients with advanced non-squamous non-small cell lung cancer .SAMSON-II is a randomized, double blind, parallel group, multicenter Phase 3 study conducted in 625 patients across 91 centers in 15 countries. Patients were randomized in a 1:1 ratio to receive HD204 or Avastin in combination with standard chemotherapy.\"These results illustrate the increasing precision with which biosimilarity can be established through advanced analytical and clinical PK studies,\" said Dr. Lisa Park, Chief Executive Officer of Prestige Biopharma. \"Our experience with HD204 supports the view that well-designed development programs can reliably anticipate cl","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.prnewswire.com/apac/news-releases/prestige-biopharma-announces-positive-topline-results-from-comparative-samson-ii-study-for-hd204-a-potential-biosimilar-to-avastin-bevacizumab-302722770.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4195","PFS","BK7095","ORR.AU","OS","BK4181","BK4211","BK4218","PBH","ORR","BK4007","PK","BK4097"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621706487","title":"Amplia Therapeutics Reports Four Additional Complete Responses and Improved Overall Survival Data in Accent Pancreatic Cancer Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2621706487","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621706487?lang=en_us&edition=fundamental","pubTime":"2026-03-23 20:45","pubTimestamp":1774269900,"startTime":"0","endTime":"0","summary":"HIGHLIGHTS Formal centralized and independent analysis of the clinical response data from the ACCENT trial has been undertaken and updated analysis provided to the CompanyThe data confirm that five (5","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/03/23/3260403/0/en/Amplia-Therapeutics-Reports-Four-Additional-Complete-Responses-and-Improved-Overall-Survival-Data-in-Accent-Pancreatic-Cancer-Trial.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4213","INNMF","OS","PFS","BK4195","BK4539","BK4161","CR","BK4139","LENZ","BK4007","BK4097","PR","BK4211","ORR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621777299","title":"Press Release: Pyxis Oncology Provides Business Update and Reports Fourth Quarter and Full Year 2025 Financial Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2621777299","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621777299?lang=en_us&edition=fundamental","pubTime":"2026-03-23 19:00","pubTimestamp":1774263600,"startTime":"0","endTime":"0","summary":"Updated data from MICVO Phase 1 monotherapy study in 2L+ R/M HNSCC on track for mid-year 2026; to include patients treated with modified weight-based dosing and patients treated with total body weight dosing. Updated data from MICVO Phase 1/2 dose escalation study in combination with KEYTRUDA in 1L/2L+ R/M HNSCC on track for the second half of 2026. Announced appointment of Thomas Civik as Interim Chief Executive Officer. Expected cash runway into the fourth quarter of 2026. BOSTON, March 23, 2026  -- Pyxis Oncology, Inc. , a clinical-stage company developing next-generation therapeutics for difficult-to-treat cancers, today provided a business update, and reported financial results for the year and quarter ended December 31, 2025.-- Pyxis Oncology announced positive preliminary data for micvotabart. -- Monotherapy: 46% confirmed objective response rate  and 92%. disease control rate  observed with MICVO as monotherapy in. 2L+ R/M HNSCC . MICVO as monotherapy was. generally well tolera","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PYXS","BK4022","L","BK4585","LU0053666078.USD","BK4588","BK4232","ORR","LU2487616109.SGD","LU0210528500.USD","BK4139","R","BK4107"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620779332","title":"Cellectis Reports Full Year 2025 Financial Results and Provides a Business Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2620779332","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620779332?lang=en_us&edition=fundamental","pubTime":"2026-03-20 07:21","pubTimestamp":1773962460,"startTime":"0","endTime":"0","summary":"Pivotal Phase 2 with lasme-cel in r/r B-ALL (BALLI-01 trial) ongoing Phase 1: 83% ORR at RP2D and 100% ORR in the target Phase 2 populationIn target Phase 2 population: 100% of patients became eligibl","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/03/19/3259513/0/en/Cellectis-Reports-Full-Year-2025-Financial-Results-and-Provides-a-Business-Update.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ASH","IE0031619046.USD","OS","BK4097","BK4006","CLLS","CRS","IE00B7SZL793.SGD","LU0963586101.USD","BK4139","LU2065731478.USD","LU2463526074.USD","IE00B19Z4B17.USD","BK4109","ORR","IE00B66KJ199.SGD","BK4187"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2619450780","title":"NovaBridge Announces Productive FDA Type B Meeting on Potential Accelerated Approval Pathway for Givastomig in Gastric Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2619450780","media":"GlobeNewswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2619450780?lang=en_us&edition=fundamental","pubTime":"2026-03-16 19:00","pubTimestamp":1773658800,"startTime":"0","endTime":"0","summary":"FDA confirmed givastomig’s potential eligibility for an accelerated approval pathwayNovaBridge expects to initiate a registrational Phase 3 combination trial as early as Q4 2026, using objective respo","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/03/16/3256129/0/en/NovaBridge-Announces-Productive-FDA-Type-B-Meeting-on-Potential-Accelerated-Approval-Pathway-for-Givastomig-in-Gastric-Cancer.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LABU","ORR","BK4585","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2619269450","title":"CytomX’s Varsetatug Masetecan (EpCAM PROBODY® ADC) Continues to Demonstrate Positive Data Supporting Potential as a New Treatment Option in Late-Line Colorectal Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2619269450","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2619269450?lang=en_us&edition=fundamental","pubTime":"2026-03-16 19:00","pubTimestamp":1773658800,"startTime":"0","endTime":"0","summary":"- Confirmed response rates in expansion cohorts of32% at 10 mg/kg Q3W dose and 20% at 8.6 mg/kg Q3W - - Estimated progression free survival of 7.1 months at 10 mg/kg and 6.8 months at 8.6 mg/kg - - Gr","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/03/16/3256138/37704/en/CytomX-s-Varsetatug-Masetecan-EpCAM-PROBODY-ADC-Continues-to-Demonstrate-Positive-Data-Supporting-Potential-as-a-New-Treatment-Option-in-Late-Line-Colorectal-Cancer.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TRAE","BK4213","LU0456854461.SGD","BK4080","BK4231","ORR","ADC","BK4211","PFS","LU0266512127.USD","BK4195","CRC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618412132","title":"SELLAS Life Sciences Announces Enrollment of First Patient in Newly Diagnosed First-Line AML Trial of SLS009","url":"https://stock-news.laohu8.com/highlight/detail?id=2618412132","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618412132?lang=en_us&edition=fundamental","pubTime":"2026-03-12 20:35","pubTimestamp":1773318900,"startTime":"0","endTime":"0","summary":"- Study to Enroll 80 Patients Unlikely to Benefit from Venetoclax/Azacitide (Aza/Ven) Therapy in the US and Europe -- SELLAS’ Predictive Biomarker and AI Assisted Precision Medicine Models to be Utili","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/03/12/3254670/0/en/SELLAS-Life-Sciences-Announces-Enrollment-of-First-Patient-in-Newly-Diagnosed-First-Line-AML-Trial-of-SLS009.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","ORR","SLS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1170989075","title":"New Variable in Pan-KRAS Space: Valuation Gap Behind JAB-23E73's 38.5% ORR in Pancreatic Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=1170989075","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1170989075?lang=en_us&edition=fundamental","pubTime":"2026-03-11 09:27","pubTimestamp":1773192420,"startTime":"0","endTime":"0","summary":"Recent disclosures in the Pan-KRAS field have revealed a set of data worthy of close examination. JACOBIO-B (01167) announced Phase I study results for JAB-23E73 in pancreatic cancer patients. The...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01167","ORR","BK1574","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618396674","title":"Press Release: Alpha Tau Announces Full Year 2025 Financial Results and Provides Corporate Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2618396674","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618396674?lang=en_us&edition=fundamental","pubTime":"2026-03-10 04:02","pubTimestamp":1773086520,"startTime":"0","endTime":"0","summary":"- Tremendous activity in recent months, including receipt of Japanese marketing approval, the fifth parallel U.S. trial approval, data from pancreatic cancer trials presented at ASCO GI Symposium, and the first brain cancer treatment -. \"The pace of progress at Alpha Tau today is unlike anything we've ever seen before,\" said Alpha Tau Chief Executive Officer Uzi Sofer. \"With a slew of meaningful announcements in the past few months, culminating most recently with our receipt of marketing approval in Japan, our first outside of Israel, and with multiple meaningful milestones targeted for the coming months, we remain laser focused on execution. Clinical trial progress remains our highest priority, with an astounding five clinical trials approved in parallel in the U.S. At the same time, we continue to build out our manufacturing capabilities in New Hampshire as well as our pre-commercial preparations, while entertaining multiple tracks of strategic dialogue with partners who show increas","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IDE","BK4232","R","DRTS","BK4022","BK4082","ORR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2617668076","title":"Press Release: PMV Pharmaceuticals Reports Full Year 2025 Financial Results and Corporate Highlights","url":"https://stock-news.laohu8.com/highlight/detail?id=2617668076","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2617668076?lang=en_us&edition=fundamental","pubTime":"2026-03-06 21:00","pubTimestamp":1772802000,"startTime":"0","endTime":"0","summary":"-- Enrollment remains on track in Phase 2 pivotal portion of PYNNACLE trial. ovarian cancer patients with a TP53 Y220C mutation. -- Rezatapopt granted Orphan Drug Designation by the U.S. Food and Drug. Administration for the treatment of TP53 Y220C positive ovarian cancer. -- New England Journal of Medicine published first-in-human rezatapopt data. showing selective reactivation of mutant p53 in advanced solid tumors. -- Cash, cash equivalents, and marketable securities of $112.9 million as of. December 31, 2025 providing expected cash runway to end of second quarter. PRINCETON, N.J., March 06, 2026  -- PMV Pharmaceuticals, Inc. , a precision oncology company pioneering the discovery and development of small molecule therapies targeting p53, today reported financial results for the full year ended December 31, 2025, and provided a corporate update.clinical trial. The multicenter, single-arm, registrational Phase 2 study. is assessing rezatapopt as monotherapy at a dose of 2000 mg once-","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4183","PMVP","BK4599","IE0009354923.USD","ODD","ALT","LU1878469433.USD","ORR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2617575291","title":"Press Release: BBOT Reports Fourth Quarter and Full Year 2025 Financial Results and Update on Corporate Progress","url":"https://stock-news.laohu8.com/highlight/detail?id=2617575291","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2617575291?lang=en_us&edition=fundamental","pubTime":"2026-03-06 05:05","pubTimestamp":1772744700,"startTime":"0","endTime":"0","summary":"-- BBOT debuted as a publicly traded oncology company developing a. -- Announced encouraging preliminary safety and efficacy data across all. three programs: BBO-8520's differentiated efficacy and safety profile as. monotherapy and at active doses in combination with pembrolizumab with a. inhibitor, and BBO-10203 showing no hyperglycemia without HbA1c. \"2025 was a transformational year for BBOT as we debuted as a public company and advanced all three of our internally discovered RAS and PI3K<ALPHA> programs into clinical development,\" said Eli Wallace, PhD, Chief Executive Officer of BBOT. \"The preliminary safety and antitumor data across BBO-8520, BBO-11818, and BBO-10203 are consistent with a differentiated therapeutic index profile and reinforce the combination thesis underlying our portfolio. We believe we are uniquely positioned to pursue concurrent suppression of both the MAPK and PI3K<ALPHA> pathways -- a strategy made possible by our wholly owned, internally designed platform, ","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BBOT","BK4213","BK4097","BK4211","BK4195","PRGS","SOC","LU0266512127.USD","LU0456854461.SGD","BK4139","ORR","PR","CRC","LU2065732104.USD","PFS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2617604541","title":"Press Release: Immatics Announces Full Year 2025 Financial Results and Business Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2617604541","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2617604541?lang=en_us&edition=fundamental","pubTime":"2026-03-05 20:00","pubTimestamp":1772712000,"startTime":"0","endTime":"0","summary":"randomized, controlled Phase 3 trial, SUPRAME, in previously treated. advanced melanoma ongoing; anzu-cel received Orphan Drug Designation from. the FDA for the treatment of both cutaneous and uveal melanoma. -- SUPRAME timelines remain unchanged; interim and final analyses remain. expected to be triggered in 2026, BLA submission in 1H 2027 and. -- IMA203CD8 PRAME Cell Therapy : Data update from ongoing Phase 1a. trial, with a focus on ovarian cancer at relevant doses, planned for. presentation at a major medical conference in 1H 2026. -- IMA402 PRAME Bispecific: RP2D determination and Phase 1 clinical data. update with focus on melanoma and gynecologic cancers treated with IMA402. monotherapy and combination with immune checkpoint inhibitor planned for. mRNA-4203 combination trial in 3Q 2025; TCER collaboration expanded. and milestone payment received in January 2026, with the first mRNA-based. TCER product candidate planned to advance into clinical development. -- Cash and cash equiv","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4195","BK4211","R","BK4232","IMTX","BK4097","BK4022","PFS","OS","ORR"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":7,"pageCount":7,"totalSize":132,"code":"91000000","status":"200"}]}}